Jane A Driver1, Xiao Zhen Zhou2, Kun Ping Lu3. 1. Geriatric Research Education and Clinical Center, VA Boston Healthcare System and the Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jdriver@partners.org. 2. Cancer Research Institute, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: xzhou@bidmc.harvard.edu. 3. Cancer Research Institute, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: klu@bidmc.harvard.edu.
Abstract
BACKGROUND: Pin1 is an intracellular signaling molecule which plays a critical but opposite role in the pathogenesis of Alzheimer's disease (AD) and many human cancers. SCOPE OF REVIEW: We review the structure and function of the Pin1 enzyme, the diverse roles it plays in cycling cells and neurons, the epidemiologic evidence for the inverse association between cancer and AD, and the potential therapeutic implications of Pin1-based therapies. MAJOR CONCLUSIONS: Pin1 is a unique enzyme that has effects on the function of target proteins by "twisting" them into different shapes. Cycling cells use Pin1 to help coordinate cell division. It is over-expressed and/or activated by multiple mechanisms in many common human cancers, and acts on multiple signal pathways to promote tumorigenesis. Inhibition of Pin1 in animal models has profound anti-tumor effects. In contrast, Pin1 is down-regulated or inactivated by multiple mechanisms in AD brains. The absence of Pin1 impairs tau function and amyloid precursor protein processing, leading to tangle- and amyloid-related pathologies and neurodegeneration in an age-dependent manner, resembling human AD. We have developed cis and trans conformation-specific antibodies to provide the first direct evidence that tau exists in distinct cis and trans conformations and that Pin1 accelerates its cis to trans conversion, thereby protecting against tangle formation in AD. GENERAL SIGNIFICANCE: Available studies on Pin1 suggest that cancer and AD may share biological pathways that are deregulated in different directions. Pin1 biology opens exciting preventive and therapeutic horizons for both cancer and neurodegeneration. This article is part of a Special Issue entitled Proline-directed Foldases: Cell Signaling Catalysts and Drug Targets.
BACKGROUND:Pin1 is an intracellular signaling molecule which plays a critical but opposite role in the pathogenesis of Alzheimer's disease (AD) and many humancancers. SCOPE OF REVIEW: We review the structure and function of the Pin1 enzyme, the diverse roles it plays in cycling cells and neurons, the epidemiologic evidence for the inverse association between cancer and AD, and the potential therapeutic implications of Pin1-based therapies. MAJOR CONCLUSIONS:Pin1 is a unique enzyme that has effects on the function of target proteins by "twisting" them into different shapes. Cycling cells use Pin1 to help coordinate cell division. It is over-expressed and/or activated by multiple mechanisms in many common humancancers, and acts on multiple signal pathways to promote tumorigenesis. Inhibition of Pin1 in animal models has profound anti-tumor effects. In contrast, Pin1 is down-regulated or inactivated by multiple mechanisms in AD brains. The absence of Pin1 impairs tau function and amyloid precursor protein processing, leading to tangle- and amyloid-related pathologies and neurodegeneration in an age-dependent manner, resembling humanAD. We have developed cis and trans conformation-specific antibodies to provide the first direct evidence that tau exists in distinct cis and trans conformations and that Pin1 accelerates its cis to trans conversion, thereby protecting against tangle formation in AD. GENERAL SIGNIFICANCE: Available studies on Pin1 suggest that cancer and AD may share biological pathways that are deregulated in different directions. Pin1 biology opens exciting preventive and therapeutic horizons for both cancer and neurodegeneration. This article is part of a Special Issue entitled Proline-directed Foldases: Cell Signaling Catalysts and Drug Targets.
Authors: T K MacLachlan; K Somasundaram; M Sgagias; Y Shifman; R J Muschel; K H Cowan; W S El-Deiry Journal: J Biol Chem Date: 2000-01-28 Impact factor: 5.157
Authors: Gustavo Ayala; Dagong Wang; Gerburg Wulf; Anna Frolov; Rile Li; Janusz Sowadski; Thomas M Wheeler; Kun Ping Lu; Lere Bao Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Mark Yarchoan; Bryan D James; Raj C Shah; Zoe Arvanitakis; Robert S Wilson; Julie Schneider; David A Bennett; Steven E Arnold Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Apar Gupta; Sarah R Preis; Alexa S Beiser; Greta L Splansky; Charles S DeCarli; Rhoda Au; Jane A Driver Journal: Adv Geriatr Med Res Date: 2019-07-04
Authors: Summer B Gibson; Diana Abbott; James M Farnham; Khanh K Thai; Hailey McLean; Karla P Figueroa; Mark B Bromberg; Stefan M Pulst; Lisa Cannon-Albright Journal: Neurology Date: 2016-05-11 Impact factor: 9.910